Filtered By:
Specialty: Neurology
Nutrition: Vitamins

This page shows you your search results in order of relevance. This is page number 19.

Order by Relevance | Date

Total 354 results found since Jan 2013.

The Relationship Between Vitamin D Concentrations and Leg Strength in Persons with Parkinson's (P2.054)
CONCLUSION: Our data does not indicate that lower vitamin D levels are associated with reduced muscle strength; there were non-significant trends to suggest the opposite. These results may be spurious or there may be a different relationship in persons with PD. Mechanisms beyond strength such as central balance control, changes in gait patterns, and cognitive function are necessary to include in intervention studies of vitamin D and balance/falls.Study Supported by: Department of Veterans Affairs CDA2 Award, OCTRI - grant number UL1 RR024140; NeuroNext (5U10NS077350-02).Disclosure: Dr. Peterson has nothing to disclose. Dr....
Source: Neurology - April 9, 2014 Category: Neurology Authors: Peterson, A., Lobb, B., Murchison, C., Quinn, J. Tags: Movement Disorders: Co-morbidities and Novel Care Models Source Type: research

Vitamin D Is A Prognostic Factor Of Amyotrophic Lateral Sclerosis And Confers Protection To Motoneurons In Vitro (P4.084)
CONCLUSIONS:Our findings suggest that vitamin D as a reliable prognostic factor of ALS and support a neuroprotective function of vitamin D on MNs in vitro.Study Supported by:Disclosure: Dr. William has received personal compensation for activities with Novartis, Merck & Co. Inc., Sanofi-Aventis Pharmaceuticals Inc., Biogen Idec, and Actelion. Dr. Tremblier has nothing to disclose. Dr. Plassot has nothing to disclose. Dr. Alphandery has nothing to disclose. Dr. Salsac has nothing to disclose. Dr. Pageot has nothing to disclose. Dr. Juntas-Morales has nothing to disclose. Dr. Scamps has nothing to disclose. Dr. Daures ha...
Source: Neurology - April 9, 2014 Category: Neurology Authors: William, C., Tremblier, B., Plassot, C., Alphandery, S., Salsac, C., Pageot, N., Juntas-Morales, R., Scamps, F., Daures, J. P., Raoul, C. Tags: ALS: Trials and Biomarkers Source Type: research

Re-evaluating Brain Death: The Potential for Treatment and Recovery after Brain Injury (P4.285)
Conclusions: Treatment-induced reversal of BD was evidenced by functional recovery across several domains. ACP neuromodulation optimizes cerebral functioning: electrical stimulation increases metabolic coupling; nutraceuticals promote healing, repair and neurotransmitter production while attenuating inflammatory cascades and free-radical damage. BD may not be definitively irreversible and deserves therapeutic consideration.Disclosure: Dr. Defina has nothing to disclose. Dr. Zakrzewski has nothing to disclose. Dr. Prestigiacomo has nothing to disclose. Dr. Machado has nothing to disclose. Dr. Bernad has nothing to disclose....
Source: Neurology - April 9, 2014 Category: Neurology Authors: Defina, P., Zakrzewski, C., Prestigiacomo, C., Machado, C., Bernad, P., Halper, J., Fellus, J. Tags: Practice, Policy, and Ethics: Stroke, Critical Care, and Other Source Type: research

Intracranial Venous Sinus Thrombosis: Report of Three Cases (P6.255)
CONCLUSIONS: Recently, the diagnosis of Intracranial Sinus Thrombosis has increased due to rising clinical awareness especially in patients with some risk factors. Initial anticoagulation with heparin is reasonable, regardless of the presence of intracranial hemorrhage. MRI and MRV have become in important diagnostic tools.Study Supported by: No oneDisclosure: Dr. Reyes Garay has nothing to disclose. Dr. Sueldo Feijoo has nothing to disclose. Dr. Gavidia Chucan has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Reyes Garay, H., Sueldo Feijoo, C., Gavidia Chucan, J. M. Tags: Cerebrovascular Disease and Interventional Neurology: Case Reports Source Type: research

Selected Health and Life Style Factors and Time to Phenoconversion in Huntington's Disease (S47.003)
CONCLUSIONS: An association between total lifetime caffeinated soda consumption and earlier HD onset was observed, but this was not seen with other caffeinated beverages and may be spurious. Other life style risk factors associated with PD or AD did not modify time to phenoconversion in HD.SUPPORT: NIH (# 2 R01 HG002449-06), National Human Genome Research Institute, National Institute of Neurological Disorders and StrokeDisclosure: Dr. Tanner has received personal compensation for activities with AbbVie and Adamas Pharmaceuticals as a scientific advisor. Dr. Marder has received personal compensation in an editorial capacit...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Tanner, C., Marder, K., Eberly, S., Biglan, K., Oakes, D., Shoulson, I. Tags: Movement Disorders: Huntington ' s Disease, Ataxia, and Wilson Source Type: research

Clinical Investigation of the Protective Effects of Palm Vitamin E Tocotrienols on Brain White Matter Clinical Sciences
Conclusions— Mixed tocotrienols were found to attenuate the progression of WMLs. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00753532.
Source: Stroke - April 28, 2014 Category: Neurology Authors: Gopalan, Y., Shuaib, I. L., Magosso, E., Ansari, M. A., Abu Bakar, M. R., Wong, J. W., Khan, N. A. K., Liong, W. C., Sundram, K., Ng, B. H., Karuthan, C., Yuen, K. H. Tags: Neuroprotectors Clinical Sciences Source Type: research

Vitamin K Antagonists and Risk of Subdural Hematoma: Meta-Analysis of Randomized Clinical Trials Clinical Sciences
Conclusions— VKA use significantly increases the risk of subdural hematoma by 3-fold relative to antiplatelet therapy. Direct-acting oral anticoagulants are associated with a significantly reduced risk of subdural hematomas versus VKAs. Based on indirect comparisons to VKAs, the risks of subdural hematoma are similar with antiplatelet monotherapies and factor Xa inhibitors.
Source: Stroke - May 27, 2014 Category: Neurology Authors: Connolly, B. J., Pearce, L. A., Hart, R. G. Tags: Coumarins Clinical Sciences Source Type: research

Nutrition and dietary supplements in neurological diseases.
Abstract "Healthy" diets and supplements are widely used for prevention and disease modification in vascular, inflammatory and degenerative neurological diseases. Apart from a large number of cross-sectional and prospective cohort studies, there are only few interventional studies on individual dietary measures. A recent study confirmed the stroke preventive effect of a Mediterranean diet rich in olive oil and nuts; a ketogenic diet reduces seizure frequency in epilepsy. Supplementation of riboflavin, magnesium and coenzyme Q10 are probably effective in migraine prophylaxis. Creatine can improve muscle strength in...
Source: Der Nervenarzt - November 19, 2014 Category: Neurology Authors: Erbguth F, Himmerich H Tags: Nervenarzt Source Type: research

Hyperhomocysteinemia and neurologic disorders: a review.
This article provides a review of the current literature on the possible roles of eHcy relevant to various neurologic disorders. PMID: 25324876 [PubMed]
Source: Journal of Clinical Neurology - December 2, 2014 Category: Neurology Tags: J Clin Neurol Source Type: research

Pontine infarction responsible for wall-eyed bilateral internuclear ophthalmoplegia syndrome
A 68-year-old man with hypertension, cardiac arrhythmia, and a mechanical heart valve replacement treated with vitamin K antagonists was admitted for the acute onset of diplopia. Neuro-ophthalmologic examination showed a bilateral exotropia in primary gaze position (wall-eyed) with bilateral adduction deficit that did not improve by convergence (figure, video at Neurology.org/cp). In lateral gaze, a horizontal nystagmus of the abducting eyes appeared. Vertical saccades were normal (video). Pupils were symmetric and reactive to light. Brain MRI with diffusion-weighted images showed an acute pontine ischemic lesion (figure)....
Source: Nature Clinical Practice - December 8, 2014 Category: Neurology Authors: Mathis, T., Ducray, F., Tilikete, C., Vighetto, A., Biotti, D. Tags: Clinical neurology examination, All Neuro-ophthalmology, Ocular motility, Diplopia (double vision), All Cerebrovascular disease/Stroke Cases Source Type: research

Inaugural Cerebral Sinovenous Thrombosis Revealing Homocystinuria in a 2-Year-Old Boy
We report on the case of a 2-year-old boy with mild psychomotor delay, who presented with nonfebrile acute ataxia. A brain computed tomographic (CT) scan showed complete thrombosis of the superior sagittal sinus, confirmed by magnetic resonance angiography and associated with a right frontal hemorrhagic infarction. Systematic screening for thrombophilia revealed homocystinuria linked to cystathionine β-synthase deficiency with underlying compound heterozygosity. The evolution was favorable after anticoagulant therapy, specific diet, and vitamin supplementation. This case is of interest because of the unusual clinical ...
Source: Journal of Child Neurology - December 23, 2014 Category: Neurology Authors: Saboul, C., Darteyre, S., Ged, C., Fichtner, C., Gay, C., Stephan, J.-L. Tags: Brief Communication Source Type: research

Vitamin D: a target for improving post‐stroke prognosis?
Source: European Journal of Neurology - January 5, 2015 Category: Neurology Authors: Y. Béjot Tags: Editorial Source Type: research

Non-Vitamin K Antagonist Oral Anticoagulants Do Not Increase Cerebral Microbleeds
Atrial fibrillation (AF) is a cardiac arrhythmia that frequently induces ischemic strokes. Nowadays, non-vitamin K antagonist oral anticoagulants (NOACs) have come into widespread use for cardiogenic embolism prevention in place of warfarin. Recently, cerebral microbleeds (CMBs) have been noticed for their potential implication in cerebral small vessel disease. We hypothesized that NOACs do not have an unfavorable influence over cerebral small vessels and investigated whether NOACs increase CMBs in AF patients in a prospective manner.
Source: Journal of Stroke and Cerebrovascular Diseases - April 3, 2015 Category: Neurology Authors: Tsukasa Saito, Yuichiro Kawamura, Nobuyuki Sato, Kohei Kano, Kae Takahashi, Asuka Asanome, Jun Sawada, Takayuki Katayama, Naoyuki Hasebe Source Type: research

A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Six-Month Clinical Trial Followed by an Open-Label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of the Phosphodiesterase Type 4 (PDE4) Inhibitor Ibudilast (MN-166) in Subjects with Amyotrophic Lateral Sclerosis (ALS) - STEP-IBUDILAST-ALS-DB-OLE-1 (I8-1B)
CONCLUSIONS: Interim evaluation of the primary objective-safety/tolerability and secondary objective-clinical endpoint responsiveness of MN-166 60 mg/day versus placebo administered for six months with riluzole in subjects with ALS will be presented for the first 30 patients. Study Supported by: Medicinova and Carolinas ALS Research FundDisclosure: Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytokinetics, Synapse, and the National Institute of Neurological Disorders and Stroke. Dr. Bravver has nothing to disclose. Dr. Sanjak has nothing to disc...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Brooks, B., Bravver, E., Sanjak, M., Langford, V., Lary, C., Alwan, M., Nemeth, J., Russo, P., Smith, N., Lucas, N., Nichols, M., Belcher, S., Wright, K., Ward, A., Holsten, S., Fischer, M., Bockenek, W., Desai, U., Lindblom, S. C., Pacicco, T., Matsuda, Tags: Advances in ALS and Other Motor Neuron Diseases Data Blitz Presentations Source Type: research

Does OSA hypercoagulability operates through Protein C and S pathways? (P7.313)
CONCLUSION: These results suggest the association of OSA with disturbance of blood coagulation and this finding urge further investigation by conducting a larger population study.Disclosure: Dr. Ayass has nothing to disclose. Dr. Hassan has nothing to disclose. Dr. Nowshad has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Ayass, M., Hassan, S., Nowshad, G. Tags: Sleep: Respiratory Disorders and Other Source Type: research